1. "GSK Faculty"
Formats
  1. Journal Article (13834)
  2. Meeting Abstract (7076)
  3. Review (514)
  4. Book Section (342)
  5. Editorial (307)
  6. Conference Paper (162)
  7. Research Letter (96)
  8. Miscellaneous (45)
  9. Correspondence (38)
  10. Guidelines (32)
  11. Book Whole (22)
Groups
  1. GSK Faculty (22468)
  2. Sloan Kettering Institute Faculty (11482)
  3. Department of Medicine (10529)
  4. Tow Center for Developmental Oncology (TCDO) (6948)
  5. Sloan Kettering Institute Postdocs (6210)
  6. Solid Tumor Oncology Division (5880)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Steven Larson (957)
  3. Jedd Wolchok (905)
  4. Cristina Antonescu (895)
  5. Kenneth Offit (788)
  6. David Solit (779)

More People

Years
  1. 2025 (296)
  2. 2024 (868)
  3. 2023 (1016)
  4. 2022 (1152)
  5. 2021 (1088)
  6. 2020 (1257)

More Years

Publications
  1. Blood (1470)
  2. Journal of Clinical Oncology (1279)
  3. Cancer Research (1104)
  4. Clinical Cancer Research (527)
  5. Modern Pathology (494)
  6. Journal of Nuclear Medicine (474)

More Publications

Publishers
  1. Nature Publishing Group (2594)
  2. American Association for Cancer Research (2194)
  3. Elsevier Inc. (1937)
  4. American Society of Hematology (1553)
  5. Cell Press (1421)
  6. American Society of Clinical Oncology (1379)

More Publishers

Results (22468)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Analysis of mouse model and development of a novel immunotherapy in myeloid malignancies
    Meeting Abstract

    Fujino, T.; Daniyan, A. F.; Abdel-Wahab, O.; Kitamura, T.
    Cancer Science (2024)

    Fulltext@MSK | Save
  • Altered RNA splicing and AML therapy resistance
    Meeting Abstract

    Wang, E.; Pineda, J.; Kim, W.; Chen, S.; Bourcier, J.; Stahl, M.; Hogg, S.; Knorr, K.; Stanley, R.; Bradley, R.; more...
    Cancer Science (2024)

    Fulltext@MSK | Save
  • Role of PD-1hiFoxp3-CD4+tumor-infiltrating lymphocytes in the immunotherapy response
    Meeting Abstract

    Zappasodi, R.; Mangarin, L. M.; Martis, S.; Orlando, A.; Schad, S.; Wolchok, J. D.; Greenbaum, B.; Merghoub, T.
    Cancer Science (2024)

    Fulltext@MSK | Save
  • RNA methylation and control of RNA and cellular fates
    Meeting Abstract

    Kharas, M. G.
    Cancer Science (2024)

    Fulltext@MSK | Save
  • Mitochondrial augmentation of hematopoietic stem and progenitor cells as a new therapeutic approach for myelodysplasia
    Meeting Abstract

    Fujino, T.; Avni, N.; Kutner, N.; Khoury, H.; Pozner, G.; Sabath, N.; Castro, C.; Fox, N.; Lewis, A. M.; Tittley, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outcomes and survival in newly diagnosed, older, acute myeloid leukemia patients from the beat AML master trial in the venetoclax/azacitidine age
    Meeting Abstract

    Borate, U.; Huang, Y.; Li Welkie, R.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with lower-intensity therapy
    Meeting Abstract

    Hoff, F. W.; Huang, Y.; Li Welkie, R.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Patel, P. A.; Collins, R. H.; Baer, M. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Proteolytic control and therapeutic targeting of oncogenic gene expression in acute myeloid leukemia
    Meeting Abstract

    Uni, M.; Steinberg, A. P.; Slavit, A.; Rha, S.; Cheng, S.; Schmalbrock, L. K.; Su, J.; Ma, J.; McPherson, A.; Mullighan, C. G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Targeting PERK arm of unfolded protein response helps to eliminate therapy-induced residual senescent-like acute myeloid leukemia cells
    Meeting Abstract

    Poigaialwar, G.; Takao, S.; Chaudhry, S.; Schmalbrock, L. K.; Gupta, V.; Kentsis, A.; Aguirre-Ghiso, J. A.; Konopleva, M.; Sosa, M. S.; Skwarska, A.
    Blood (2024)

    Fulltext@MSK | Save
  • Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with relapsed or refractory, splicing factor-mutant myeloid malignancies
    Meeting Abstract

    Bewersdorf, J. P.; Mi, X.; Lu, B.; Kuykendall, A. T.; Sallman, D.; Patel, M.; Stevens, D. A.; Philipovskiy, A.; Sutamtewagul, G.; Masarova, L.; more...
    Blood (2024)

    Fulltext@MSK | Save